Immunovant, Inc.
Financials
Valuation Metrics
Immunovant, Inc.'s Market Cap is $7.59B. At end of 2025 it was $4.61B. Ranked #1071 of 3,121 in US market (top 34%), #352 of 1,463 on NASDAQ (top 24%), #58 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 22%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $7.59B | US#1,071/3,121 Sec#58/266 |
| Revenue | $7M | US#2,845/3,121 Sec#176/266 |
| Net Income | $-538M | US—/3,121 Sec—/266 |
| Total Assets | $852M | US#2,544/3,121 Sec#115/266 |
| Net Assets | $735M | US#1,979/3,121 Sec#83/266 |
| Employees | 315 | US#2,409/3,121 Sec#108/266 |
| Value | ||
| P/B | 10.32x | US#2,632/3,121 Sec#198/266 |
| FCF Yield | -5.46% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -73.19% | US#2,759/3,121 Sec#190/266 |
| ROA | -63.13% | US#3,023/3,121 Sec#232/266 |
| Op. Margin | -7877.46% | US#2,869/3,121 Sec#185/266 |
| Financial Health | ||
| Debt Ratio | 15.92% | US#182/3,121 Sec#71/266 |
| Total Debt | $0.00 | US—/3,121 Sec—/266 |
| FCF | $-414M | US#2,884/3,121 Sec#246/266 |
| Cash | $798M | US#793/3,121 Sec#38/266 |
| Current Ratio | 7.27x | US#346/3,121 Sec#108/266 |
| Performance | ||
| 1Y Return | 139.94% | US#107/3,121 Sec#43/266 |
| 1M Return | -17.82% | US#2,809/3,121 Sec#218/266 |
| From 52W High | -18.65% | US#1,295/3,121 Sec#88/266 |
| 1Y MDD | -19.08% | US#641/3,121 Sec#22/266 |
| Trading | ||
| Volume | 2,809,337 shares | US#1,196/3,121 Sec#121/266 |
| Trading Value | $105M | US#1,303/3,121 Sec#98/266 |
| Per Share | ||
| EPS | $-2.62 | US—/3,121 Sec—/266 |
| BPS | $3.58 | US#2,413/3,121 Sec#151/266 |
Company Info
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.